Search Results
1. Summary of results Code System Frequency DBT/MDMA-AT overlap 83 Concerns for MDMA-AT for BPD (+) 15 Modification for BPD Dx 5 Regression 4 Limitations of DBT/MDMA-AT treatment alone 0 Limitations of traditional treatment modalities (not/MDMA
/Self-Validation 4 Emotional Dysregulation 6 Understanding Emotions 4 Emotional Self-Validation 7 Wise Mind 2 Support Network 5 Stigma-Lack of Access 10 De-Stigmatization 2 Lack of Access 5 Phase 2-MDMA-AT 0 MDMA Therapy Orientation 6 Therapist Role 2 Suicidality 5
Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) have been at the forefront of addressing PTSD by working to make 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy into a legal prescription
Introduction ±3,4-Methylenedioxymethamphetamine (MDMA), the active ingredient of the street drug Ecstasy, was studied initially as an adjunct psychotherapeutic tool, prior to its nationwide prohibition. It was first termed
psychotherapeutic and pharmacologic interventions, cases of full remission usually make up a minority of outcomes ( Alexander, 2012 ; Schottenbauer et al., 2008 ). The treatment modality of 3,4-Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT) for PTSD has
people with various drug dependence, all which are described later. To date, 3,4,-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy research has focused primarily on post-traumatic stress disorder (PTSD). However, MDMA has never been explored as
,4-methylenedioxymethamphetamine (MDMA) being used for a variety of indications ( Costandi, 2014; Passie, 2018 ). Current clinical research is exploring the safety and efficacy of psychedelics for mental health disorders, such as posttraumatic stress disorder (PTSD), mood
,4,-methylenedioxymethamphetamine (MDMA)-assisted therapist training program and have served as therapists with the MAPS-sponsored trials of MDMA-assisted treatment of PTSD at NYUSoM. Currently, both authors are also part of a team conducting a qualitative interview study of
% ( n = 38) reported using LSD, 6% ( n = 6) reported using ketamine, 8% ( n = 8) reported mixing a psychedelic with another psychedelic or MDMA, 2% ( n = 2) reported using DMT, 1% ( n = 1) reported using ayahuasca and 1% ( n = 1) reported using 2
for psychedelic-assisted treatments currently. For example, a recent Phase III trial of MDMA-assisted treatment for post-traumatic stress disorder represents years of herculean work performed in multiple nations and reveals a promising effect size of
